slides · global inventory
Expose Contradiction
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 14,162
Current window 10,081-10,110
Pages 473
Rows per page 30
Slide function
10,081-10,110 of 14,162
185
QuantumScape (QS)QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
186
The slide uses direct quotes to undermine the credibility of the CEO's projections.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
187
Uses a quote from a VW employee to validate the argument.QuantumScape (QS) · Scorpion Capital
Activist deck Short seller Loop · Cost Of Inaction1 hit
03
The slide uses anonymous expert testimony to undermine the company's clinical trial integrity and market prospects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
07
The slide uses a screenshot of a Facebook post to undermine the clinical trial results of the drug VYKAT.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
12
Uses social media screenshots as primary evidence to build a case against the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
13
Uses anecdotal evidence from Facebook groups to build a case for systemic safety issues.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
14
The slide uses a specific social media post as a case study to infer broader safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
15
Uses a screenshot of a Facebook group post as primary evidence to support the claim of medical danger.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
16
Uses direct quotes from Facebook posts to highlight patient safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
17
The slide highlights a discrepancy between the FDA label's explicit warnings about DKA and the company's omission of this risk in their phase 3 and open-label manuscripts.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
20
The slide uses direct excerpts from a medical paper to build a case against the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
21
The slide uses a direct quote from the Pediatric Endocrine Society guidelines to expose the company's failure to address known side effects in their trial design.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
22
The slide uses a direct quote from a medical paper to expose the ineffectiveness of the company's recommended treatment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
23
The slide uses direct quotes from a KOL to build a case against the safety of a drug (Vykat) in the context of PWS.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
28
The slide uses screenshots of Facebook group posts as primary evidence of adverse drug reactions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
29
Uses patient testimonials as primary evidence to challenge the safety profile of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
30
The slide uses direct quotes from Facebook groups to undermine the product's safety/efficacy narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
32
The slide uses social media engagement (comment counts) as a proxy for negative sentiment and community concern.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
33
Uses a CEO quote to highlight a potential contradiction between management narrative and market reality.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
34
The slide uses a screenshot of a Soleno clinical trial flow diagram to highlight patient drop-off.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
35
The slide uses a Q&A transcript format to build a narrative of a cover-up regarding drug safety.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
36
The slide uses a Q&A format to highlight potential corporate malfeasance regarding clinical trial safety reporting.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
37
The slide uses a 'villain' narrative by framing patient advocacy groups as manipulators of the regulatory process.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
38
The slide uses an excerpt from the FDA label to critique the clinical trial design.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
39
The slide uses a red box to highlight a specific time period in the C602-RWP study to question the validity of the efficacy results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
40
The slide uses a combination of narrative summary and direct Q&A transcript excerpts to build a case of potential clinical trial misconduct.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
02
This is a text-heavy regulatory filing document, likely part of a petition to the FDA regarding safety concerns.Soleno Therapeutics (SLNO) · Kir Kahlon
Regulatory filing Short seller Beat · Problem & Complication1 hit
03
This appears to be a page from a regulatory filing or activist short report, focusing on adverse event reporting and potential obfuscation by the manufacturer.Soleno Therapeutics (SLNO) · Kir Kahlon
Regulatory filing Short seller Beat · Problem & Complication1 hit
06
This appears to be a page from an activist short report or regulatory challenge document.Soleno Therapeutics (SLNO) · Kir Kahlon
Regulatory filing Short seller Beat · Desire1 hit